ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3225

Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behcet’s Disease

Mikhail Ognenovski1, Paul Renauer1, Ina Koetter2, Joerg C. Henes3, Bruno Casali4, Carlo Salvarani5, Haner Direskeneli6, Kenneth M. Kaufman7 and Amr H. Sawalha1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Internal Medicine IV Rheumatology, Asklepios Klinik Altona, Hamburg, Germany, 3Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, 4Divisione di Biologia Molecolare, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, 5Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy, 6Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 7Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Behcet's syndrome, genetics, genomics and polymorphism

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis IV

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Behcet’s disease (BD) is a systemic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and other organ complications such as vascular, central nervous system, and gastrointestinal involvement. The etiology and pathogenesis of BD are poorly understood. Despite the identification of multiple common genetic variants associated with BD, rare genetic variants have been less explored. We performed whole exome sequencing (WES) in a European-derived cohort of BD patients to investigate the role of rare protein-coding variants in this disease.

Methods: Whole exome sequencing was initially performed in 14 BD patients of European descent. Exome enrichment was performed using the TrueSeq Exome Enrichment Kit (Illumina), then paired-end 100bp reads were sequenced on an Illumina HiSeq 2000 instrument. Sequence alignment, quality assurance measures, and data analysis were performed using the DNA-Seq Analysis Package (SVS 7) implemented in Golden Helix. Sanger sequencing and Sequenom technology genotyping were performed in the original patient set and two additional independent European-derived sets for validation and replication. Protein damaging potential for non-synonymous coding variants was assessed using SIFT, Polyphen, Mutation Taser, Mutation Assessor, and FATHMM. 

Results: We identified 77 protein-coding non-synonymous variants in 74 genes detected in at least 2 out of 14 re-sequenced BD patients, with a minor allele frequency (MAF)<0.01 in 6,500 control individuals included in the NHLBI Exome Sequencing Project, and predicted to have protein damaging effect. Sanger sequencing in selected variants confirmed our exome sequencing results. Genotyping was successfully performed and passed quality control measures in 61 variants in two additional sets of 49 and 129 European-derived BD patients from Germany and Italy, respectively. Genetic analysis was performed in BD cases compared to 503 European-derived controls included in the 1000 Genomes Project. Two rare protein-coding non-synonymous genetic variants were significantly associated with BD with a Bonferroni-corrected P value of <8X10-4. We detected an association with non-synonymous potentially damaging variants in LIMK2 which is involved in actin cytoskeleton organization, and the DNA repair gene NEIL1. 

Conclusion: We used whole exome sequencing in BD for the first time, and identified rare non-synonymous protein-coding variants associated with this disease.


Disclosure: M. Ognenovski, None; P. Renauer, None; I. Koetter, None; J. C. Henes, None; B. Casali, None; C. Salvarani, None; H. Direskeneli, None; K. M. Kaufman, None; A. H. Sawalha, None.

To cite this abstract in AMA style:

Ognenovski M, Renauer P, Koetter I, Henes JC, Casali B, Salvarani C, Direskeneli H, Kaufman KM, Sawalha AH. Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behcet’s Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/whole-exome-sequencing-identifies-rare-protein-coding-variants-in-behcets-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-exome-sequencing-identifies-rare-protein-coding-variants-in-behcets-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology